Ninepoint Partners LP increased its stake in Johnson & Johnson (NYSE:JNJ) by 11.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,636 shares of the company’s stock after purchasing an additional 276 shares during the quarter. Ninepoint Partners LP’s holdings in Johnson & Johnson were worth $392,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. increased its holdings in Johnson & Johnson by 0.6% during the 2nd quarter. BlackRock Inc. now owns 193,714,044 shares of the company’s stock valued at $27,242,005,000 after acquiring an additional 1,168,129 shares in the last quarter. Morgan Stanley boosted its position in shares of Johnson & Johnson by 0.3% in the first quarter. Morgan Stanley now owns 20,801,433 shares of the company’s stock worth $2,727,694,000 after acquiring an additional 54,563 shares during the last quarter. Nordea Investment Management AB boosted its position in shares of Johnson & Johnson by 88.0% in the second quarter. Nordea Investment Management AB now owns 17,222,162 shares of the company’s stock worth $2,382,514,000 after acquiring an additional 8,062,204 shares during the last quarter. Swiss National Bank boosted its position in shares of Johnson & Johnson by 1.4% in the second quarter. Swiss National Bank now owns 11,304,866 shares of the company’s stock worth $1,589,803,000 after acquiring an additional 157,100 shares during the last quarter. Finally, California Public Employees Retirement System boosted its position in shares of Johnson & Johnson by 2.2% in the second quarter. California Public Employees Retirement System now owns 9,752,233 shares of the company’s stock worth $1,371,457,000 after acquiring an additional 210,973 shares during the last quarter. Institutional investors and hedge funds own 67.44% of the company’s stock.
A number of research analysts have weighed in on the stock. Stifel Nicolaus cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Bank of America reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 20th. Credit Suisse Group boosted their target price on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research note on Wednesday. SVB Leerink reissued an “outperform” rating on shares of Johnson & Johnson in a report on Wednesday, July 15th. Finally, Zacks Investment Research downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price target for the company. in a report on Tuesday, July 7th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $164.93.
In related news, EVP Ashley Mcevoy sold 29,000 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the transaction, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Kathryn E. Wengel sold 16,115 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the completion of the transaction, the executive vice president now owns 66,658 shares in the company, valued at approximately $10,233,336.16. The disclosure for this sale can be found here. 0.27% of the stock is owned by company insiders.
Shares of NYSE:JNJ opened at $148.10 on Friday. Johnson & Johnson has a twelve month low of $109.16 and a twelve month high of $157.00. The firm has a market cap of $389.92 billion, a PE ratio of 23.29, a price-to-earnings-growth ratio of 3.36 and a beta of 0.68. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.99 and a current ratio of 1.25. The business has a fifty day moving average of $148.57 and a 200-day moving average of $146.59.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.98 by $0.22. The company had revenue of $21.08 billion during the quarter, compared to analyst estimates of $20.15 billion. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same period last year, the company posted $2.12 earnings per share. On average, analysts anticipate that Johnson & Johnson will post 8 EPS for the current fiscal year.
Johnson & Johnson Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Read More: Why are gap-down stocks important?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.